Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Viking Therapeutics (NASDAQ: VKTX) reported its Q1 2023 financial results on April 26, 2023, highlighting significant developments in its clinical pipeline. The company completed enrollment in the Phase 2b VOYAGE study of VK2809 for NASH and fibrosis, with data expected in Q2 2023. Viking also announced Phase 1 results for VK2735, showcasing up to 6% placebo-adjusted weight loss and a strong safety profile. The initiation of a Phase 1 trial for an oral formulation of VK2735 was also noted. Financially, Viking completed a public offering raising $287.5 million, enhancing its cash position to approximately $406 million. However, the net loss for the quarter increased to $19.5 million, or $0.25 per share, compared to a loss of $16.1 million, or $0.21 per share in 2022.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, will release its financial results for the first quarter of 2023 on April 26, 2023, post-market close. A conference call to discuss the results and corporate updates is scheduled for 4:30 p.m. Eastern Time on the same day. Investors can participate by dialing (844) 850-0543 within the U.S. or (412) 317-5199 internationally. The call will also be available via live webcast and can be replayed until May 3, 2023. Viking Therapeutics focuses on developing therapies for metabolic and endocrine disorders and has three compounds in clinical trials, including VK2809, which is in a Phase 2b study for treating non-alcoholic steatohepatitis.
On April 11, 2023, Viking Therapeutics (NASDAQ: VKTX) announced that its CEO, Brian Lian, Ph.D., will present at the 22nd Annual Needham Healthcare Conference. The conference is scheduled for April 17-20, 2023, with Viking's presentation set for 10:15 a.m. Eastern on April 18, 2023. This virtual event will feature corporate presentations and one-on-one meetings between management and investors.
Viking Therapeutics specializes in developing novel therapies for metabolic and endocrine disorders, with three compounds under clinical trials. Notable projects include VK2809, targeting non-alcoholic steatohepatitis (NASH) and VK2735, aimed at metabolic disorders. The company’s expertise in metabolism drives its innovative therapeutic approach.
Viking Therapeutics (Nasdaq: VKTX) announced the closing of a public offering of 19,828,300 shares of common stock at $14.50 per share, generating gross proceeds of approximately $287.5 million. The underwriters exercised their option to purchase an additional 2,586,300 shares. Proceeds will fund the continued development of VK2809, VK2735, and VK0214 programs, alongside general research and development. The offering was conducted under an effective shelf registration statement filed with the SEC. Notably, Viking's clinical programs target metabolic and endocrine disorders, with promising developments in treatments for NASH and X-ALD.
Viking Therapeutics, Inc. (NASDAQ: VKTX) has priced its public offering of 17,242,000 shares at $14.50 per share, aiming for gross proceeds of approximately $250 million. The offering is set to close on or about April 3, 2023. Underwriters have a 30-day option to purchase an additional 2,586,300 shares. Funds will support ongoing development of VK2809, VK2735, VK0214, and general research and development. The public offering is conducted under an effective shelf registration statement filed with the SEC. Viking focuses on innovative therapies for metabolic and endocrine disorders, with compounds in active clinical trials.
Viking Therapeutics (Nasdaq: VKTX) announced a proposed underwritten public offering of its common stock on March 29, 2023. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares sold. Viking intends to utilize the net proceeds for the development of its clinical programs, including VK2809, VK2735, and VK0214, as well as for general corporate purposes. The public offering will occur under a shelf registration statement previously filed with the SEC. No assurance is given regarding the completion of the offering or its terms.